MRNA

Moderna, Inc. [MRNA] Stock Forecast

Q: What is Moderna, Inc. stock symbol ?

Moderna, Inc. is a US stock, located in Cambridge of Ma and trading under the symbol MRNA

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

MRNA Stock Summary

EPS has increased from the previous quarter and is now positive. (Quarter statements)

MRNA has more than 10 years of cash runway (122 months)

Earnings are expected to fall -100% next year

EPS has been decreasing for the past 3 years (Yearly statements)

Top 10 Correlated Stocks

MRNA

In the News

MRNA Financial details

Company Rating

Buy

Market Cap

40.26B

Income

-4.71B

Revenue

6.85B

Book val./share

36.36

Cash/share

22.58

Dividend

Dividend %

Employees

5.6K

Optionable

Shortable

Yes

Earnings

02 May 2024

P/E

-12.11

Forward P/E

PEG

0.76

P/S

4.61

P/B

3.12

P/C

4.47

P/FCF

-15.81

Quick Ratio

2.15

Current Ratio

2.46

Debt / Equity

0.09

LT Debt / Equity

0.09

EPS (TTM)

-12.38

EPS next Y

EPS next Q

EPS this Y

-158.15%

EPS next Y

EPS next 5Y

EPS last 5Y

51.42%

Revenue last 5Y

168.9%

Revenue Q/Q

53.63%

EPS Q/Q

-105.98%

SMA20

-0.95%

SMA50

7.22%

SMA100

33.33%

Inst Own

53.1%

Inst Trans

0.84%

ROA

-18%

ROE

-20%

ROC

-0.18%

Gross Margin

38%

Oper. Margin

-29%

Profit Margin

-38%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

62.55-163.24

52W High

-38.12%

52W Low

+62.69%

RSI

Rel Volume

0.45

Avg Volume

3.96M

Volume

1.8M

Perf Week

-5.74%

Perf Month

-2.1%

Perf Quarter

40.27%

Perf Half Y

16.84%

Beta

1.586

Volatility

1.35%, 3.03%

Prev Close

-1.11%

Price

100.87

Change

-1.62%

MRNA Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0.15	0.72	44.01	48.89	17.68
Net income per share	-1.55	-1.96	30.28	21.22	-12.34
Operating cash flow per share	-1.39	5.32	33.8	12.64	-8.16
Free cash flow per share	-1.48	5.14	33.09	11.63	-10.01
Cash per share	3.33	12.08	26.62	25.13	22.52
Book value per share	3.55	6.72	35.1	48.54	36.27
Tangible book value per share	3.55	6.72	35.1	48.54	36.02
Share holders equity per share	3.55	6.72	35.1	48.54	36.27
Interest debt per share	0.62	1.8	2.32	3.12	3.35
Market cap	6.47B	39.84B	102.35B	70.77B	37.99B
Enterprise value	6.37B	37.42B	96.42B	68.77B	36.33B
P/E ratio	-12.59	-53.33	8.39	8.46	-8.06
Price to sales ratio	134.7	145.13	5.77	3.67	5.62
POCF ratio	-14.1	19.65	7.51	14.21	-12.18
PFCF ratio	-13.19	20.33	7.68	15.45	-9.93
P/B Ratio	5.51	15.55	7.24	3.7	2.74
PTB ratio	5.51	15.55	7.24	3.7	2.74
EV to sales	132.55	136.33	5.44	3.57	5.38
Enterprise value over EBITDA	-11.67	-49.04	7.25	7.04	-11.31
EV to operating cash flow	-13.87	18.46	7.08	13.81	-11.65
EV to free cash flow	-12.98	19.1	7.23	15.01	-9.5
Earnings yield	-0.08	-0.02	0.12	0.12	-0.12
Free cash flow yield	-0.08	0.05	0.13	0.06	-0.1
Debt to equity	0.17	0.26	0.06	0.06	0.09
Debt to assets	0.13	0.09	0.04	0.05	0.07
Net debt to EBITDA	0.19	3.17	-0.45	-0.21	0.52
Current ratio	8.82	1.43	1.92	2.73	3.42
Interest coverage	-82.53	-77.19	738.67	324.83	-111.55
Income quality	0.89	-2.71	1.12	0.6	0.66
Dividend Yield	0	0	0	0	0.01
Payout ratio	0	-0.01	0.01	0.02	-0.06
Sales general and administrative to revenue	2.28	0	0	0	0
Research and developement to revenue	10.33	4.99	0.11	0.17	0.72
Intangibles to total assets	0	0	-0.06	0	0.01
Capex to operating cash flow	0.07	-0.03	-0.02	-0.08	0.23
Capex to revenue	-0.66	-0.25	-0.02	-0.02	-0.1
Capex to depreciation	-1.02	-2.16	-1.22	-1.15	-1.14
Stock based compensation to revenue	1.69	0.34	0.01	0.01	0.05
Graham number	11.14	17.21	154.63	152.24	100.35
ROIC	-0.36	-0.22	0.76	0.39	-0.31
Return on tangible assets	-0.32	-0.1	0.47	0.32	-0.26
Graham Net	0.75	2.4	8.43	11.88	12.94
Working capital	1.12B	1.91B	8.44B	8.51B	7.31B
Tangible asset value	1.17B	2.56B	15.64B	19.12B	13.76B
Net current asset value	848.38M	1.52B	7.05B	6.7B	5.75B
Invested capital	0.17	0.26	0.06	0.06	0.09
Average receivables	23.44M	713.41M	2.35B	2.34B	1.23B
Average payables	19.15M	12.72M	160.18M	394.5M	503.5M
Average inventory	-538.59M	-428.83M	743.76M	1.2B	575.5M
Days sales outstanding	123.83	1.88K	67.83	26.24	58.42
Days payables outstanding	83.42	844.7	42.12	32.82	40.44
Days of inventory on hand	-10.64K	2.14K	200.98	63.96	15.71
Receivables turnover	2.95	0.19	5.38	13.91	6.25
Payables turnover	4.38	0.43	8.67	11.12	9.03
Inventory turnover	-0.03	0.17	1.82	5.71	23.23
ROE	-0.44	-0.29	0.86	0.44	-0.34
Capex per share	-0.1	-0.18	-0.7	-1.02	-1.85

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric	2022-12-31	2023-03-31	2023-06-30	2023-09-30	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	13.21	4.82	0.9	4.81	7.38
Net income per share	3.81	0.2	-3.62	-9.53	0.57
Operating cash flow per share	4.32	-3.17	-2.4	-4.2	1.63
Free cash flow per share	4.08	-3.47	-3.02	-4.57	1.06
Cash per share	25.72	23.12	22.2	19.88	22.58
Book value per share	49.67	48.87	44.49	35.31	36.36
Tangible book value per share	49.67	48.61	44.23	35.06	36.11
Share holders equity per share	49.67	48.87	44.49	35.31	36.36
Interest debt per share	3.14	2.71	3.1	3.51	3.28
Market cap	69.15B	59.28B	46.29B	39.35B	37.89B
Enterprise value	67.15B	56.77B	43.44B	37.69B	36.23B
P/E ratio	11.8	187.6	-8.39	-2.71	43.65
Price to sales ratio	13.6	31.84	134.57	21.49	13.47
POCF ratio	41.61	-48.39	-50.59	-24.6	60.92
PFCF ratio	44.05	-44.31	-40.29	-22.62	94.25
P/B Ratio	3.62	3.14	2.73	2.92	2.73
PTB ratio	3.62	3.14	2.73	2.92	2.73
EV to sales	13.21	30.49	126.27	20.59	12.88
Enterprise value over EBITDA	42.5	-197.11	-24.47	-21.38	120.75
EV to operating cash flow	40.4	-46.34	-47.47	-23.56	58.24
EV to free cash flow	42.77	-42.43	-37.8	-21.66	90.12
Earnings yield	0.02	0	-0.03	-0.09	0.01
Free cash flow yield	0.02	-0.02	-0.02	-0.04	0.01
Debt to equity	0.06	0.06	0.07	0.1	0.09
Debt to assets	0.05	0.05	0.05	0.07	0.07
Net debt to EBITDA	-1.27	8.73	1.61	0.94	-5.55
Current ratio	2.73	3.46	3.39	2.46	3.42
Interest coverage	158	6	-143.62	-201.2	1
Income quality	1.13	-15.51	0.66	0.44	2.87
Dividend Yield	0	0	0	0	0
Payout ratio	0	0.32	-0.03	-0.02	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0.24	0.61	3.34	0.63	0.5
Intangibles to total assets	0	0	0	0	0.01
Capex to operating cash flow	-0.06	0.09	0.26	0.09	-0.35
Capex to revenue	-0.02	-0.06	-0.68	-0.08	-0.08
Capex to depreciation	-1.15	-1.45	-2.54	-0.56	-1.09
Stock based compensation to revenue	0.01	0.04	0.22	0.04	0.03
Graham number	65.21	15	60.21	87.01	21.59
ROIC	0.07	0	-0.08	-0.23	0
Return on tangible assets	0.06	0	-0.06	-0.19	0.01
Graham Net	12.16	12.6	10.64	8.45	12.98
Working capital	8.51B	8.62B	7.48B	6.41B	7.31B
Tangible asset value	19.12B	18.76B	16.85B	13.36B	13.76B
Net current asset value	6.7B	6.86B	5.66B	4.8B	5.75B
Invested capital	0.06	0.06	0.07	0.1	0.09
Average receivables	2.1B	1.25B	672.5M	1.05B	1.47B
Average payables	408.5M	438M	349.5M	402M	507M
Average inventory	1.51B	840.5M	723.5M	601M	344.5M
Days sales outstanding	24.52	53.8	60.7	91.72	34.59
Days payables outstanding	22.85	44.2	38.17	19.84	50.38
Days of inventory on hand	44.53	83.18	88.03	19.56	19.57
Receivables turnover	3.67	1.67	1.48	0.98	2.6
Payables turnover	3.94	2.04	2.36	4.54	1.79
Inventory turnover	2.02	1.08	1.02	4.6	4.6
ROE	0.08	0	-0.08	-0.27	0.02
Capex per share	-0.24	-0.29	-0.61	-0.37	-0.58

MRNA Frequently Asked Questions

What is Moderna, Inc. stock symbol ?

Moderna, Inc. is a US stock , located in Cambridge of Ma and trading under the symbol MRNA

What is Moderna, Inc. stock quote today ?

Moderna, Inc. stock price is $100.87 today.

Is Moderna, Inc. stock public?

Yes, Moderna, Inc. is a publicly traded company.

Something similar

Top by Market Cap

Same Sector

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 3.96M
Market Capitalization 40.26B
Employee 5.6K
CEO Mr. Stephane Bancel
Headquarters Cambridge,MA,US
IPO Date 2018-12-07
Website https://www.modernatx.com

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.